I. Introduction {#sec1}
===============

Most FDA-approved drugs are small organic molecules that elicit a therapeutic response by binding to a target biological macromolecule. Once bound, small molecule ligands either inhibit the binding of other ligands or allosterically adjust the target's conformational ensemble. Binding is thus crucial to any behavior of a therapeutic ligand. To maximize a molecule's therapeutic effect, its affinity---or binding free energy (Δ*G*)---for the desired targets must be maximized, while simultaneously minimizing its affinity for other macromolecules. Historically, scientists have used both cheminformatic and structure-based approaches to model ligands and their targets, and most machine learning (ML) approaches use domain-expertise-driven features.

More recently, deep neural networks (DNNs) have been translated to the molecular sciences. Training most conventional DNN architectures requires vast amounts of data: for example, ImageNet^[@ref1]^ currently contains over 14 000 000 labeled images. In contrast, the largest publicly available data sets for the properties of druglike molecules include PDBBind 2017,^[@ref2]^ with a little over 4000 samples of protein--ligand cocrystal structures and associated binding affinity values; Tox21 with nearly 10 000 small molecules and associated toxicity end points; QM8 with around 22 000 small molecules and associated electronic properties; and ESOL with a little over 1000 small molecules and associated solubility values.^[@ref3]^ This scarcity of high-quality scientific data necessitates innovative neural architectures for molecular machine learning.

Successful DNNs often exploit relevant structure in data, such as pixel proximity in images. Predicting protein--ligand binding affinity seems to resemble computer vision problems. Just as neighboring pixels connote closeness between physical objects, a binding pocket could be divided into a voxel grid. Here, neighboring voxels denote neighboring atoms and blocks of empty space. Unfortunately, this 3D convolutional approach has several potential drawbacks. First, inputs and hidden weights require much more memory in three dimensions. Second, since the parameters grow exponentially with the number of dimensions, the model suffers from the "curse of dimensionality":^[@ref4]^ while image processing may entail a square 3^2^ filter, the corresponding filter for volumetric molecule processing has 3^3^ parameters.

In contrast, graph convolutions use fewer parameters by exploiting molecular structure and symmetry. Consider a carbon bonded to four other atoms. A 3D convolutional neural network (CNN) would need several different filters to accommodate the subgroup's symmetrically equivalent orientations. However, a graph convolution as described in refs ([@ref5]−[@ref8]) is symmetric to permutations and relative location of each of the four neighbors, thereby significantly reducing the number of model parameters. The use of graph convolutional approaches to learn molecular properties is reminiscent of the familiar canon of chemoinformatics algorithms such as Morgan fingerprints,^[@ref9]^ SMILES strings,^[@ref10]^ and the Ullman algorithm for substructure search,^[@ref11]^ all of which enrich chemical descriptions by propagating information about neighboring atoms.

In this paper, we first review a subset of DNN architectures applicable to protein--ligand interaction. Through the mathematical frameworks above, we contextualize our presentation of new models that generalize a graph convolution to include both intramolecular interactions and noncovalent interactions between different molecules. We describe a staged gated graph neural network, which distinguishes the derivation of differentiable bonded atom types from the propagation of information between different molecules. Finally, we address a potential shortcoming of the standard benchmark in this space---namely, treating the PDBBind 2007 core set as a fixed test set---by choosing a cross-validation strategy that more closely resembles the reality of drug discovery. Though more challenging, this benchmark may better reflect a given model's generalization capacity.

II. Neural Network Architectures {#sec2}
================================

First, we briefly review a subset of DNN architectures applicable to protein--ligand interaction to motivate the new models we present and test at the end of the paper.

II.A. Ligand-Based Scoring Models {#sec2.1}
---------------------------------

### II.A.1. Fully Connected Neural Networks {#sec2.1.1}

The qualitatively simplest models for affinity prediction and related tasks incorporate only features of ligands and ignore the macromolecular target(s). Such a model could entail a fully connected neural network (FCNN), in which each molecule is represented by a flat vector *x* containing *f*~0~ features. Then, these features are updated through "hidden" layers *h* by applying nonlinear activation functions.

The training data for such a network consists of a set of *N* molecules, each represented by a vector of length *f*~0~, which have a one-to-one correspondence with a set of *N* affinity labels. Domain-expertise-driven flat vector features might include integer counts of different types of predetermined functional groups (e.g., carboxylic acids, aromatic rings), polar or nonpolar atoms, and other ligand-based features. Cheminformatic featurizations include extended circular fingerprints (ECFP)^[@ref12]^ and ROCS.^[@ref13],[@ref14]^

### II.A.2. Graph Convolutional Neural Networks {#sec2.1.2}

In convolutional neural networks (CNNs), each layer convolves the previous layer's feature map with linear kernels followed by elementwise nonlinearities, producing new features of higher complexity that combine information from neighboring pixels.^[@ref15]^ A graph convolutional neural network (GCNN) analogously exploits the inherent structure of data.^[@ref16]^ We can represent a given graph that contains *N* nodes, *f*~in~ features per node, and a single edge type, as consisting of node features *x* and symmetric adjacency matrix *A*, which designates whether a pair of nodes belong to each other's neighbor sets *N*. Consider the molecule propanamide ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). For the carbonyl carbon, the relevant row of the feature matrix *x* might be \[1, 0, 0\] to represent its element, and the corresponding row of the adjacency matrix *A* might be \[0, 1, 0, 1, 1\] to indicate its bonds to three neighbor atoms.

![Visual depiction of the gated graph neural network with atoms as nodes and bonds as edges. The small molecule propanamide is chosen to illustrate the propagation of information among the different update layers of the network.](oc-2018-00507j_0001){#fig1}

A graph convolution update, as summarized in ref ([@ref8]), entails applying a function at each node that takes the node and its neighbors as input and outputs a new set of features for each node. It can be written aswhere *h*~*i*~^(*t*)^ represents the node features of node *i* at hidden layer *t*, *N*(*v*~*i*~) represents the neighbors of node *i*, and *U*^(*t*)^ and *m*^(*t*)^ are the update and message functions, respectively, at hidden layer *t*. When there are multiple edge types, we must define multiple message functions, *m*^(*t*,*e*)^, which is the message function at layer *t* for edge type *e* ∈ \[1, ···, *N*~*et*~\].

Our models are primarily inspired by the gated graph neural networks (GGNNs).^[@ref7]^ At all layers, the update function is the familiar gated recurrent unit (GRU). Message functions are simple linear operations that are different for each edge type but also the same across layers:where *A*^(*e*)^ is the adjacency matrix, and *W*^(*e*)^ the weight matrix, respectively, for edge type *e*.

Unlike conventional FCNNs, which learn nonlinear combinations of the input hand-crafted features, the update described in [eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"} learns nonlinear combinations of more basic features of a given atom with the features of its immediate neighbors. Information propagates through increasingly distant atoms with each graph convolution, and the GRU enables information to be added selectively. Ultimately, the GGNN contains and leverages both per-node features via the feature matrix *x* and structural information via the adjacency matrix *A*. In both classification and regression settings, GCNNs terminate in a "graph gather" step that sums over the rows of the final embeddings and is invariant to node ordering. The subsequent FCNNs produce output of desired size (*f*~out~). This completes the starting point for the graph convolutional update used in this paper:

### II.A.3. Generalization to Multitask Settings {#sec2.1.3}

Predicting affinity for multiple targets by GCNN can be implemented by training either different models for each target or by training a single multitask network. The latter setting has a last weight matrix , where *T* denotes the number of targets in the data set. The corresponding multitask loss function would be the average binary cross-entropy loss across the targets

II.B. Structure-Based Scoring Models {#sec2.2}
------------------------------------

Since the advent of biomolecular crystallography by Perutz et al.,^[@ref17]^ the drug discovery community has sought to leverage structural information about the target in addition to the ligand. Numerous physics-based approaches have attempted to realize this, including molecular docking,^[@ref18]−[@ref21]^ free energy perturbation,^[@ref22]^ and quantum mechanics/molecular mechanics (QM/MM),^[@ref23]^ among others. More recent approaches include RF-Score,^[@ref24],[@ref25]^ NN-Score,^[@ref26]^ Grid Featurizer,^[@ref3]^ three-dimensional CNN approaches,^[@ref27],[@ref28]^ and Atomic Convolutional Neural Networks.^[@ref29]^

### II.B.1. PotentialNet Architectures for Molecular Property Prediction {#sec2.2.1}

To motivate architectures for more principled DNN predictors, we invoke the following notation and framework. First, we introduce the distance matrix , whose entries *R*~*ij*~ denote the distance between atom~*i*~ and atom~*j*~. Thus far, the concept of adjacency, as encoded in a symmetric matrix *A*, has been restricted to chemical bonds. However, adjacency can also encompass a wider range of neighbor types to include noncovalent interactions (e.g., π--π stacking, hydrogen bonds, hydrophobic contact). Adjacency need not require domain expertise: pairwise distances below a threshold value can also be used. Regardless of a particular scheme, we see how the distance matrix *R* motivates the construction of an expanded version of *A*. In this framework, *A* becomes a tensor of shape *N* × *N* × *N*~et~, where *N*~et~ represents the number of edge types.

If we order the rows by the membership of atom~*i*~ to either the protein or ligand, we can view both *A* and *R* as block matrices, where the diagonal blocks are self-edges (i.e., bonds and noncovalent interactions) from one ligand atom to another ligand atom or from one protein atom to another protein atom, whereas off-diagonal block matrices encode edges from the protein to the ligand and from ligand to protein. For illustration purposes, we choose the special case where there is only one edge type, *N*~et~ = 1:where *A*~*ij*~ is 1 for neighbors and 0 otherwise, and . Within this framework, we can mathematically express a *spatial graph convolution*---a graph convolution based on notions of adjacency predicated on Euclidean distance---as a generalization of the GGNN characterized by the update, [eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"}.

In addition to edge type generalization, we introduce nonlinearity in the message portion of the graph convolutional layer:where *NN*^(*e*)^ is a neural network for each edge type *e* and *N*^(*e*)^(*h*~*i*~) denotes the neighbors of edge type *e* for atom/node *i*.

Finally, we generalize the concept of a layer to the notion of a *stage* that can span several layers of a given type. The staged PotentialNet consists of three main steps: (1) covalent-only propagation, (2) dual noncovalent and covalent propagation, and (3) ligand-based graph gather (see [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). Stage 1, covalent propagation, entails only the first slice of the adjacency matrix, *A*^(1)^, which contains a 1 at entry (*i*, *j*) if there is a bond between (atom~*i*~, atom~*j*~) and a 0 otherwise. Intuitively, stage 1 computes a new set of vector-valued atom types *h*~*i*~^(b)^ for each of the *N* atoms in the system based on their local networks of bonded atoms (see [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Subsequently, stage 2 entails propagation based on both the full adjacency tensor *A* which begins with the vector-valued atom types *h*~*i*~^(sp)^ computed in [eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}. While stage 1 computes new bond-based "atom types" for both amino acid and ligand atoms, stage 2 passes both bond and spatial information between the atoms. For instance, if stage 1 distinguishes an amide carbonyl oxygen from a ketone carbonyl oxygen, stage 2 might communicate in the first layer that that carbonyl oxygen is also within 3 Å of a hydrogen bond donor (see [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). Finally, in stage 3 a graph gather is performed solely on the ligand atoms. The ligand-only graph gather is made computationally straightforward by the block matrix formulation described in [eq [5](#eq5){ref-type="disp-formula"}](#eq5){ref-type="disp-formula"}.where *i*^(b)^, *j*^(b)^, *i*^(sp)^, *j*^(sp)^ are (b)ond and (sp)atial neural networks, and *h*~*j*~^(sp)^ denotes the feature map for the *j*^th^ atom at the end of stage 2.

![Visual depiction of multistaged spatial gated graph neural network. Stage 1 entails graph convolutions over only bonds, which derives new node (atom) feature maps roughly analogous to differentiable atom types in more traditional forms of molecular modeling. Stage 2 entails both bond-based and spatial distance-based propagation of information. In the final stage, a graph gather operation is conducted over the ligand atoms, whose feature maps are derived from bonded ligand information and spatial proximity to protein atoms.](oc-2018-00507j_0002){#fig2}

![PotentialNet stage 1 exploits only covalent or bonded interaction edge types encoded in the first slices of the last dimension of the adjacency tensor *A*.](oc-2018-00507j_0003){#fig3}

![PotentialNet stage 2 exploits both bonded and nonbonded interaction edge types spanning the entirety of the last dimension of the adjacency tensor *A*.](oc-2018-00507j_0004){#fig4}

A theoretically attractive concept in [eq [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"} is that atom types---the 1 × *f*~*b*~ per-atom feature maps---are derived from the same initial features for both ligand and protein atoms. In contrast to molecular dynamics force fields,^[@ref30]^ which---for historical reasons---have distinct force fields for ligands and for proteins which then must interoperate (often poorly) in simulation, our approach derives the physicochemical properties of biomolecular interactions from a unified framework.

To further illustrate this, PotentialNet stage 1 and stage 2 exploit different subsets of the full adjacency tensor *A*.

III. Measuring Early Enrichment in Regression Settings for Virtual Screening {#sec2.3}
============================================================================

Traditional metrics of predictor performance suffer from general problems and drug discovery-specific issues. For regressors, both *R*^2^---the "coefficient of determination"---and the root-mean-square error (RMSE) are susceptible to single data point outliers. The RMSE for both classifiers and regressors account for neither the training data distribution nor the null model performance. The area under the receiver operating characteristic curve (AUC)^[@ref31]^ does correct this deficiency in RMSE for classifiers. However, all aforementioned metrics are global statistics that equally weight all data points. This property is particularly undesirable in drug discovery, which is most interested in predicting the tails of a distribution: while model predictions are made against an entire library containing millions of molecules, one will only purchase or synthesize the top scoring molecules. In response, the cheminformatics community has adopted the concept of *early enrichment*. Methods like BEDROC^[@ref32]^ and LogAUC^[@ref33]^ weight the importance of the model's highest performers more heavily.

III.A. Proposed Metric: EF~χ~^(*R*)^ {#sec2.4}
------------------------------------

At present, this progress in early enrichment measurement has been limited to classification and has yet to include regression. Therefore, we propose a new metric for early enrichment in regression, the Regression Enrichment Factor, EF~χ~^(*R*)^, analogous to EF~χ~. For a given targetin which *y*~*i*~ values, the experimental (observed) measurement for sample *i*, are ranked in descending order according to *ŷ*~*i*~, the model (predicted) measurement for sample *i*. In other words, we compute the average z-Score for the observed values of the top χ% scoring samples. We prefer this approach to computing, for example, 1/χ·*N*∑~*i*~^χ·*N*^(*y*~*i*~ -- *y̅*), which has units that are the same as *y*~*i*~ (i.e., log(*K*~*i*~) values). Unfortunately, this unnormalized approach depends on the distribution in the data set. For instance, in a distribution of log(*K*~*i*~) measurements, if the maximum deviation from the mean is 1.0, the best a model can possibly perform would be to achieve an EF~χ~^(*R*)^ of 1.0.

We normalize through division by σ(*y*), the standard deviation of the data. This allows comparison of model performance across data sets with a common unit of measurement but different variances in those measurements. The upper bound is therefore equal to the right-hand side of [eq [10](#eq10){ref-type="disp-formula"}](#eq10){ref-type="disp-formula"}, where the indexed set of molecules *i* constitutes the subset of the χ·*N* most experimentally active molecules. This value is dependent on both the distribution of the training data as well as the value χ. The EF~χ~^(*R*)^ is an average over χ·*N* z-scores, which themselves are real numbers of standard deviations away from the mean experimental activity.^[@ref34]^

IV. Results {#sec3}
===========

IV.A. Cross-Validation Strategies {#sec3.1}
---------------------------------

It is well-known that the performance of DNN algorithms is highly sensitive to chosen hyperparameters. Such sensitivity underscores the criticality of rigorous cross-validation.^[@ref35],[@ref36]^ Several recent papers, including works that claim specifically to improve binding affinity prediction on the PDBBind data set,^[@ref37],[@ref38]^ engage in the practice of searching hyperparameters *directly on the test set*. Compounding this problem is a fundamental deficiency of the main cross-validation procedure used in this subfield that is discussed below.

While there are newer iterations of the PDBBind data set, e.g., ref ([@ref2]), we choose to evaluate performance on PDBBind 2007^[@ref39],[@ref40]^ to compare performance of our proposed architectures to previous methods. In previous works, the PDBBind 2007 data set was split by (1) beginning with the "refined" set comprising 1300 protein--ligand cocrystal structures and associated binding free energy; (2) removing the "core" set comprising 195 samples to form the test set, with (3) the remaining 1095 samples serving as the training data. We term this train--test split "PDBBind 2007, Refined Train, Core Test" below, and compare performance with RF-Score,^[@ref25]^ X-Score,^[@ref41],[@ref42]^ and [networks [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"}--[9](#eq9){ref-type="disp-formula"} described in this work.

One drawback to train--test split is possible overfitting to the test set through hyperparameter searching. Another limitation is that train and test sets will contain similar examples. Whereas it is typical in other machine learning disciplines for the train and test set examples to be drawn from the same statistical distributions, such a setting is not necessarily desirable in a molecular machine learning setting.^[@ref43]^ Drug discovery campaigns typically involve the synthesis and investigation of novel chemical matter. To accurately assess the generalizability of a trained model, the cross-validation strategy should reflect how that model will be deployed practically. In context of this reasoning, the "Refined Train, Core Test" strategy is not optimal for cross-validation. For example, ref ([@ref44]) showed that systematically removing samples from the PDBBind 2007 refined set with structural or sequence homology to the core (test) set significantly attenuated the performance of recent ML-based methods for affinity prediction.

Therefore, we propose and investigate a cross-validation strategy that splits all data into three distinct folds---train, validation, and test subsets---with agglomerative hierarchical clustering based on pairwise structural and sequence homology of the *proteins* as distance metrics.^[@ref45],[@ref46]^[Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} contrasts this technique with other common splitting methods for ligand binding studies. Both sequence and structural similarity measures are described in ref ([@ref44]). The agglomerative clustering procedure is described in detail in ref ([@ref45]) and is a specific case of the method introduced in ref ([@ref46]). Our cross-validation on the PDBBind 2007 refined set with sequence similarity resulted in 978 train samples, 221 valid samples, and 101 test samples (75%--17%--8%); meanwhile, clustering on structural similarity yielded 925 train samples, 257 valid samples, and 118 test samples (71%--20%--9%). A [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00507/suppl_file/oc8b00507_si_001.txt) file is provided with the two sets of train, validation, and test assignments.

![Notional comparison of cross-validation splitting algorithms. The first four vertical panels from the left depict simple examples of random split, stratified split, time split, and scaffold split. The rightmost panel depicts a toy example of the agglomerative split proposed in this work. Both scaffold split and agglomerative split group similar data points together to promote the generalizability of the network to new data. Scaffold split uses the algorithm introduced by Bemis and Murcko^[@ref47]^ to group ligands into common frameworks. The agglomerative split uses hierarchical agglomerative clustering to group ligand--protein systems according to pairwise sequence or structural similarity of the proteins. This figure is adapted from ref ([@ref3]) with permission from the Royal Society of Chemistry.](oc-2018-00507j_0005){#fig5}

IV.B. Performance of Methods on Benchmarks {#sec3.2}
------------------------------------------

On the standard PDBBind 2007 "Refined Train, Core Test" benchmark, the PotentialNet Spatial Graph Convolution achieves state-of-the-art performance as reflected by several metrics. PotentialNet outperforms RF-Score and X-Score according to Pearson and Spearman correlation coefficients. The Pearson correlation score for [eqs [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"}--[9](#eq9){ref-type="disp-formula"} is within error of the reported score for TopologyNet, the heretofore top performing model on this benchmark. However, a key caveat must be noted with respect to this comparison: all cross-validation for this Article, including all of our results reported in [Tables [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}--[3](#tbl3){ref-type="other"}, was performed such that performance on the *test* set was recorded for the hyperparameter set that performed most highly on the *validation* set. In contrast, in the TopologyNet study,^[@ref37]^ models were trained on a *combination* of the validation and training sets and evaluated *directly on the test set*. Performance for TopologyNet^[@ref37]^ therefore reflects a train--validation type split rather than a train--validation--test split, which likely inflated the performance of that method.

###### Benchmark: PDBBind 2007, Refined Train, Core Test[a](#tbl1-fn1){ref-type="table-fn"}

  model                                 Test *R*^2^     Test EF~χ~^(*R*)^   Test Pearson    Test Spearman       Test stdev      Test MUE
  ------------------------------------- --------------- ------------------- --------------- ------------------- --------------- ---------------
  PotentialNet                          0.668 (0.043)   1.643 (0.127)       0.822 (0.021)   **0.826** (0.020)   1.388 (0.070)   0.626 (0.037)
  PotentialNet, (ligand-only control)   0.419 (0.234)   1.404 (0.171)       0.650 (0.017)   0.670 (0.014)       1.832 (0.135)   0.839 (0.005)
  TopologyNet, no validation set        N/A             N/A                 **0.826**       N/A                 N/A             N/A
  RF-Score                              N/A             N/A                 0.783           0.769               N/A             N/A
  X-Score                               N/A             N/A                 0.643           0.707               N/A             N/A

Error bars are recorded as standard deviation of the test metric over three random initializations of the best model as determined by average validation set score. MUE is mean unsigned error. Pearson test scores for TopologyNet are reported from ref ([@ref37]), and RF- and X-Scores are reported from ref ([@ref44]).

###### Benchmark: PDBBind 2007 Refined, Agglomerative Sequence Split[a](#tbl2-fn1){ref-type="table-fn"}

  model                      Test *R*^2^         Test EF~χ~^(*R*)^   Test Pearson        Test Spearman   Test MUE
  -------------------------- ------------------- ------------------- ------------------- --------------- -------------------
  PotentialNet               0.480 (0.030)       0.867 (0.036)       0.700 (0.003)       0.694 (0.012)   1.680 (0.061)
  ligand-only PotentialNet   0.414 (0.058)       0.883 (0.025)       0.653 (0.031)       0.674 (0.020)   1.712 (0.110)
  RF-Score                   **0.527** (0.014)   1.078 (0.143)       **0.732** (0.009)   0.723 (0.013)   **1.582** (0.034)
  X-Score                    0.470               **1.117**           0.702               **0.764**       1.667

Error bars are recorded as standard deviation of the test metric over three random initializations of the best model as determined by average validation set score. MUE is mean unsigned error. X-Score does not have error because it is a deterministic linear model.

###### Benchmark: PDBBind 2007 Refined, Agglomerative Structure Split[a](#tbl3-fn1){ref-type="table-fn"}

  model                      Test *R*^2^         Test EF~χ~^(*R*)^   Test Pearson        Test Spearman       Test MUE
  -------------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  PotentialNet               **0.629** (0.044)   **1.576** (0.053)   **0.823** (0.023)   **0.805** (0.019)   **1.553** (0.125)
  ligand-only PotentialNet   0.500 (0.010)       1.498 (0.411)       0.733 (0.007)       0.726 (0.005)       1.700 (0.067)
  RF-Score                   0.594 (0.005)       0.869 (0.090)       0.779 (0.003)       0.757 (0.005)       1.542 (0.046)
  X-Score                    0.517               0.891               0.730               0.751               1.751

Error bars are recorded as standard deviation of the test metric over three random initializations of the best model as determined by average validation set score. MUE is mean unsigned error. X-Score does not have error because it is a deterministic linear model.

Intriguingly, the gap in performance between the PotentialNet Spatial Graph Convolution and the other tested statistical models changes considerably on the agglomerative structure and sequence split benchmarks. On sequence split, RF-Score achieves the best overall performance, followed by a statistical tie between the Staged Spatial Graph Convolution, [eqs [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"}--[9](#eq9){ref-type="disp-formula"} , and X-Score, followed by the ligand-only graph convolutional control. Meanwhile, on structure split, PotentialNet achieves the highest overall performance, followed by RF-Score, followed by a statistical tie of X-Score, and the graph convolutional ligand-only control.

It is noteworthy that the PotentialNet Spatial Graph Convolutions ([eqs [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"}--[9](#eq9){ref-type="disp-formula"}) perform competitively with other compared methods when the proposed Spatial Graph Convolutions are predicated on very simple, per-atom features and pure notions of distance whereas RF-Score, X-Score, and TopologyNet all directly incorporate domain-expertise-driven information on protein--ligand interactions.

### IV.B.1. Sanity Check with a Traditional RNN {#sec3.2.1}

Given the unreasonable effectiveness of deep learning methods in mostly unstructured settings, it is important to justify our incorporation of domain knowledge over a purely deep learning-based approach. To do this, we trained a bidirectional long short-term memory (LSTM) network, a commonly used recurrent neural network (RNN) that handles both past and future context well. We represented the protein--ligand complexes using a sequential representation of protein--ligand complexes in PDBBind: proteins were one-hot encoded by amino acid, and ligands were similarly encoded on a character-level using their SMILES string representation. The test Pearson correlation coefficient corresponding to the best validation score (using the same metric) was 0.518, far worse than our results and justifying our model's incorporation of domain knowledge.

IV.C. Ligand-Based Models {#sec3.3}
-------------------------

While crystallography, NMR, and, most recently, cryoelectron microscopy have opened a new paradigm of structure-based drug design, many critical tasks of drug discovery can be predicted from the chemical composition of a given molecule itself, without explicit knowledge of the macromolecule(s) to which they bind. Such properties include electronic spectra (important for parametrizing small molecule force fields for molecular dynamics simulations, for example), solubility, and animal toxicity.

Quantum mechanical data sets are particularly ripe for machine learning algorithms since it is straightforward to generate training data at some known accuracy. The QM8 data set,^[@ref48]^ which contains several electronic properties for small molecules in the GDB-8 set, lends itself particularly well for benchmarking PotentialNet [eqs [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"}--[9](#eq9){ref-type="disp-formula"} since each compound's properties are calculated based on the three-dimensional coordinates of each element. The ESOL solubility^[@ref49]^ and Tox21 toxicity^[@ref50]^ data sets map two-dimensional molecular representations consisting solely of atoms and their bonds to their respective single-task and multitask outputs, and therefore serve as validation of our neural network implementations as well as of the value of incorporating nonlinearity into the message function.

To summarize, our computational experiments indicate that PotentialNet leads to statistically significant improvements in performance for all three investigated ligand-based tasks. For the QM8 data set, we were able to directly assess the performance benefit that stems from separating spatial graph convolutions into distinct stages. Recall that stage I of PotentialNet, [eq [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"}, propagates information over only bonds and therefore derives differentiable "atom types", whereas stage II of PotentialNet, [eq [8](#eq8){ref-type="disp-formula"}](#eq8){ref-type="disp-formula"}, propagates information over both bonds and different binned distances. We performed an experiment with QM8 in which stage I was essentially skipped, and graph convolutions propagated both covalent and noncovalent interactions without a privileged first stage for only covalent interactions. Clearly, separating the two stages led to a significant boost in performance.

For each ligand model investigation we benchmark against the error suggested upon introduction of the data set, or to enable direct comparison with previously published approaches. For extensive benchmarking of various models on these and other data sets, we refer the reader to ref ([@ref3]).

### IV.C.1. Quantum Property Prediction {#sec3.3.1}

[Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"} reports the performances in mean absolute error (MAE) over 21 786 compounds and 12 tasks in QM8. We utilize MAE for consistency with the original proposal of the database.^[@ref48]^ Multiple PotentialNet variants and two mature deep learning models, deep tensor neural network^[@ref51]^ (DTNN) and message passing neural network^[@ref8]^ (MPNN), are evaluated, in which the latter two models proved to be successful on quantum mechanical tasks (e.g., atomization energy^[@ref3]^). We restricted the training length to 100 epochs and performed 100 rounds of hyperparameter search on PotentialNet models. The staged spatial PotentialNet model achieved the best performances in the group, demonstrating strong predictive power on the tasks. We have also included taskwise results in [Appendix B](#app2){ref-type="other"}.

###### Quantum Property Prediction with QM8 Data Set[a](#tbl4-fn1){ref-type="table-fn"}

  network                              Valid MAE   Test MAE
  ------------------------------------ ----------- ---------------------
  spatial PotentialNet, staged         0.0120      **0.0118** (0.0003)
  spatial PotentialNet, SingleUpdate   0.0133      0.0131 (0.0001)
  MPNN                                 0.0142      0.0139 (0.0007)
  DTNN                                 0.0168      0.0163 (0.0010)

Error bars are recorded as standard deviation of the test metric over three random initializations of the best model as determined by average validation set score.

###### Toxicity Prediction with the Tox21 Data Set[a](#tbl5-fn1){ref-type="table-fn"}

  network        Valid ROC--AUC   Test ROC--AUC
  -------------- ---------------- -------------------
  PotentialNet   0.878            **0.857** (0.006)
  Weave          0.852            0.831 (0.013)
  GraphConv      0.858            0.838 (0.001)
  XGBoost        0.778            0.808 (0.000)

Error bars are recorded as standard deviation of the test metric over three random initializations of the best model as determined by average validation set score.

###### Solubility Prediction with the Delaney ESOL Data Set[a](#tbl6-fn1){ref-type="table-fn"}

  network        Valid RMSE   Test RMSE
  -------------- ------------ -------------------
  PotentialNet   0.517        **0.490** (0.014)
  Weave          0.549        0.553 (0.035)
  GraphConv      0.721        0.648 (0.019)
  XGBoost        1.182        0.912 (0.000)

Error bars are recorded as standard deviation of the test metric over three random initializations of the best model as determined by average validation set score.

### IV.C.2. Toxicity {#sec3.3.2}

In the multitask toxicity benchmark, we evaluated the performances of two graph convolutional type models^[@ref5],[@ref16]^ and PotentialNet on the Tox21 data set under the same evaluation pattern (see [Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}). With 100 epochs of training, PotentialNet demonstrated higher ROC--AUC scores on both validation and test scores, outperforming Weave and GraphConv by a comfortable margin.

### IV.C.3. Solubility {#sec3.3.3}

The same three models are also tested and compared on a solubility task,^[@ref49]^ using RMSE to quantify the error to compare to previous work.^[@ref16]^ PotentialNet achieved slightly smaller RMSE than Weave and GraphConv ([Table [6](#tbl6){ref-type="other"}](#tbl6){ref-type="other"}). Under the limited 100 epochs training, the final test RMSE is comparable or even superior to the best scores reported for Weave and GraphConv (0.46^[@ref5]^ and 0.52,^[@ref16]^ respectively).

V. Discussion {#sec4}
=============

Spatial Graph Convolutions exhibit state-of-the-art performance in affinity prediction. Whether based on linear regression, random forests, or other classes of DNNs, all three of RF-Score, X-Score, and TopologyNet are machine learning models that explicitly draw upon traditional physics-based features. Meanwhile, the Spatial Graph Convolutions presented here use a more principled deep learning approach. Input features are only basic information about atoms, bonds, and distances. This framework does not use traditional hand-crafted features, such as hydrophobic effects, π-stacking, or hydrogen bonding. Instead, higher-level interaction "features" are learned through intermediate graph convolutional neural network layers.

The traditional PDBBind 2007 benchmark uses 1105 samples from the refined set for training and 195 from the core set for testing. Here, Spatial Graph Convolutions outperform X-Score and RF-Score and perform comparably with TopologyNet (even though this searched hyperparameters directly over the test data set). On our proposed agglomerative clustering cross-validation benchmark, the choice of sequence or structure split affects relative performance. On sequence split, RF-Score achieved the highest overall performance, with Staged Spatial Graph Convolutions and X-Score statistically tied for second. However, on structure split, the Staged Spatial Graph Convolutions performed best, with RF-Score in second place.

While the Pearson correlation was employed in the preceding performance comparison, instead, comparing methods through EF~χ~^(*R*)^ tells a mildly different story. On the agglomerative sequence cross-validation split, in which test proteins are separated from train proteins based on amino acid sequence deviation, X-Score statistically ties RF-Score for the best model, while PotentialNet statistically ties the ligand-only PotentialNet control for last place at over 0.1 average standard deviations worse than X-Score and RF-Score for the top 5% of predictions. Meanwhile, using the agglomerative structure cross-validation split, PotentialNet exceeds the performance of X-Score and RF-Score by over 0.5 average standard deviations, although it is within a statistical tie of the ligand-only PotentialNet control (which has a surprisingly high variance in its EF~χ~^(*R*)^). Taken together, we aver that it is important for the future of ML-driven structure-based drug discovery to carefully choose both (1) the cross-validation technique and (2) the metric of performance on held-out test set to most accurately reflect the capacity of their models to generalize in simulated realistic settings.

In light of the continued importance and success of ligand-based methods in drug discovery, we benchmarked PotentialNet on several ligand based tasks: electronic property (multitask), solubility (single task), and toxicity prediction (multitask). Statistically significant performance increases were observed for all three prediction tasks. A potentially step change improvement was observed for the QM8 challenge which also reinforced the value of the concept of stages that privilege bonded from nonbonded interactions (see [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}).

Despite the simpler input featurization, Spatial Graph Convolutions can learn an accurate mapping of protein--ligand structures to binding free energies using the same relatively low amount of data as previous expertise-driven approaches. We thus expect that as larger sets of training data become available, Spatial Graph Convolutions can become the gold standard in affinity prediction. Unfortunately, such larger, publicly available data sets are currently nonexistent. We thus call upon academic experimental scientists and/or their pharmaceutical industry counterparts to release as much high-quality protein--ligand binding affinity data as possible so the community can develop and benefit from better affinity prediction models.

Due to the field's immense practical applications, our algorithms must prioritize realizable results over incremental improvements on somewhat arbitrary benchmarks. We thus also present a new benchmark score and accompanying cross-validation procedure. The latter draws on agglomerative clustering of sequence and structural similarity to construct challenging train--test splits. Using this proposed cross-validation schema, on sequence-based splitting ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) we observe in the Pearson correlation column that RF-Score exceeds X-Score, and X-Score statistically ties Spatial Graph Convolutions. For structure-based splitting ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}) we observe that Spatial Graph Convolutions exceeds both RF-Score and X-Score in the Pearson correlation column. We highlight the Pearson correlation for consistency with the literature, but present other metrics in [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"} from which similar conclusions could be drawn.

This construction (i.e., choice of cross-validation schema) helps assess models with a practical test set, such as one containing newly designed compounds on previously unseen protein targets. Although standard machine learning practice draws train and test sets from the same distribution, if machine leaning is to be applied to real-world drug discovery settings it is imperative that we accurately measure a given model's capacity both to interpolate within familiar regions of chemical space as well as to generalize to its less charted territories.

VI. Methods {#sec4.1}
===========

VI.A. Models {#sec4.1.1}
------------

DNNs were constructed and trained with PyTorch.^[@ref52]^ Custom Python code was used based on RDKit^[@ref53]^ and OEChem^[@ref54]^ with frequent use of NumPy^[@ref55]^ and SciPy.^[@ref56]^ Networks were trained on chemical element, formal charge, hybridization, aromaticity, and the total numbers of bonds, hydrogens (total and implicit), and radical electrons. Random forest and linear regression models (i.e., X-Score) were implemented using scikit-learn;^[@ref57]^ all random forests models were trained with 500 trees and 6 features per tree, and the implementation of X-Score is described in ref ([@ref44]). Hyperparameters for PotentialNet models trained for binding affinity, electronic properties, toxicity, and solubility studies are given in [Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"}; for toxicity and solubility models, only bond graph convolution layers are employed since there are no 3D coordinates provided for the associated data sets. For these three tasks, random splitting was used for cross-validation. For the RNN sanity check of the ligand binding task, the best-performing LSTM sanity check was constructed with 5 layers, a hidden size of 32, 10 classes, and a learning rate of 3.45e--4.

###### Hyperparameters for Neural Networks ([equations [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"}--[9](#eq9){ref-type="disp-formula"})

  network        hyperparameter name                    symbol                          possible values
  -------------- -------------------------------------- ------------------------------- ----------------------------------------------------------
  PotentialNet   gather widths (bond and spatial)       *f*~bond~, *f*~spatial~         \[64, 128\]
  PotentialNet   number of bond convolution layers      bond~*K*~                       \[1, 2\]
  PotentialNet   number of spatial convolution layers   spatial~*K*~                    \[1, 2, 3\]
  PotentialNet   gather width                           *f*~gather~                     \[64, 128\]
  PotentialNet   number of graph convolution layers     *K*                             \[1, 2, 3\]
  both           fully connected widths                 *n*~rows~ of *W*^(*FC*~*i*~)^   \[\[128, 32, 1\], \[128, 1\], \[64, 32, 1\], \[64, 1\]\]
  both           learning rate                                                          \[1e--3, 2e--4\]
  both           weight decay                                                           \[0., 1e--7, 1e--5, 1e--3\]
  both           dropout                                                                \[0., 0.25, 0.4, 0.5\]

VI.B. Cross-Validation on PDBBind 2007 Core Test Set Benchmark {#sec4.1.2}
--------------------------------------------------------------

The core set was removed from the refined set sorted temporally to create the test set. Up to 8 hyperparameters were tuned through random search. *K*-fold temporal cross-validation was conducted within the train set for each hyperparameter set. For each held-out fold, validation set performance was recorded at the epoch with maximal Pearson correlation coefficient between the labeled and predicted values in the validation set. For each hyperparameter set, the validation score was the average Pearson score over the *K* folds using the best epoch for each fold. The set with the best validation score was then used to evaluate test performance. The training set was split into *K* temporal folds; for each fold, test set performance was recorded at the epoch with highest validation score. All reported metrics are given as the median with the standard deviation over K folds in parentheses.

VI.C. Cross-Validation on PDBBind 2007 Structure and Sequence Agglomerative Clustering Split Benchmarks {#sec4.1.3}
-------------------------------------------------------------------------------------------------------

Agglomerative clustering was performed with Ward's method.^[@ref58]^ Pairwise distance between PDB proteins was measured as either 1.0 minus the sequence homology or the TMScore.^[@ref59]^ Within the train set, for each hyperparameter set, *K* random splits within the train set were performed. For each held-out fold, validation set performance was recorded at the epoch with maximal Pearson correlation coefficient. The set with the best average Pearson score on the validation set was used to evaluate test set performance. The training set was again randomly split into *K* folds; for each fold, test set performance was recorded at the epoch at which the held-out performance was highest according to Pearson score. Metrics are reported as detailed above.

Here, we consider the complexity of the various neural architectures discussed in [Section [II](#sec2){ref-type="other"}](#sec2){ref-type="other"}, starting with the simple fully connected setting. Forward propagation can be understood as passing an input vector *x* of length *n* through *h* matrix multiplications, each , and *h* elementwise nonlinear activation layers, each . Assuming *h* ≪ *n*, this yields a total complexity of . Since back-propagation involves the same dimensions and number of layers, just in reverse order, it has the same complexity as the forward operation.

Complexity analysis for a 2D convolutional neural network, typical in computer vision tasks, is a bit more involved. An *m*- × *n*-dimensional filter on an *M* × *N* image yields *m* × *n* computations on *M* × *N* pixels, in total . Using the fast Fourier transform for optimized processing, a single convolutional layer will be , the same complexity as the entire network. Notice that these operations' costs grow exponentially with the dimension of Euclidean data---making the exploitation of symmetry far more important for 3D graph data.

The GGNN family of graph convolutional architectures includes effective optimizations to reduce complexity on graphs. Let *d* be the dimension of each node's internal hidden representation and *n* be the number of nodes in the graph. A single step of message passing for a dense graph requires multiplications. Breaking the *d* dimensional node embeddings into *k* different dimensional embeddings reduces this runtime to . As most molecules are sparse or relatively small graphs, these layers are typically . Although other optimizations exist, such as utilizing spectral representations of graphs, the models presented in this work build around this general GGNN framework with different nonlinearities and update rules. None of these are sufficiently computationally expensive enough to alter the total runtime.

In [Table [8](#tbl8){ref-type="other"}](#tbl8){ref-type="other"} we have recorded the test set performances for all 12 tasks in the QM8 data set using the MAE for a deep tensor neural network^[@ref51]^ (DTNN), a message passing neural network^[@ref8]^ (MPNN), and the staged and single update Spatial PotentialNet networks as in [Section [II.B.1](#sec2.2.1){ref-type="other"}](#sec2.2.1){ref-type="other"}.

###### QM8 Test Set Performances of All Tasks (Mean Absolute Error)

  task       DTNN     MPNN     PotentialNet, single update   PotentialNet, staged
  ---------- -------- -------- ----------------------------- ----------------------
  E1--CC2    0.0092   0.0084   0.0070                        **0.0068**
  E2--CC2    0.0092   0.0091   0.0079                        **0.0074**
  f1--CC2    0.0182   0.0151   0.0137                        **0.0134**
  f2--CC2    0.0377   0.0314   0.0296                        **0.0285**
  E1--PBE0   0.0090   0.0083   0.0070                        **0.0067**
  E2--PBE0   0.0086   0.0086   0.0074                        **0.0070**
  f1--PBE0   0.0155   0.0123   0.0112                        **0.0108**
  f2--PBE0   0.0281   0.0236   0.0228                        **0.0215**
  E1--CAM    0.0086   0.0079   0.0066                        **0.0063**
  E2--CAM    0.0082   0.0082   0.0069                        **0.0064**
  f1--CAM    0.0180   0.0134   0.0123                        **0.0117**
  f2--CAM    0.0322   0.0258   0.0245                        **0.0233**
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